About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

India to Go in for Foreign Tie-ups to Boost Research in Biotech

by Gopalan on November 22, 2008 at 6:56 PM
Font : A-A+

 India to Go in for Foreign Tie-ups to Boost Research in Biotech

India is embarking on a series of foreign tie-ups to boost research and train manpower for its burgeoning biotech industry.

Under a new agreement between India's Department of Biotechnology (DBT) and the London-based Wellcome Trust, 75 fellowships are to be awarded every year for ten years from now.

Advertisement

The Ģ160 million project is aimed at attracting the best Indian biomedical scientists working abroad.

Last year, the Indian government and Stanford University, California, launched a five-year $4.8-million 'biodesign program' aimed at turning Indian doctors and engineers into medical device inventors and impelling India's biomedical technology industry, says Rajiv Doshi, the program's executive director at Stanford.
Advertisement

Canada also pledged Ca$5 ($4.3) million for a fund to support plant biotech research, and another joint fund was set up with 3 ($4) million from the European Commission to support agricultural biotech research in April 2008.

An Indo-Norwegian alliance has been launched to focus on vaccines, and a bioinformatics collaboration with Japan is on the cards.

An $11.5 million Indo-Australian joint fund has been supporting public and private sector researchers since 2006 in the fields of stem cells, vaccines and transgenic crops. Academic scientists have benefited, but the fruits of these alliances have yet to flow to companies, says Prasanta Ghosh, former adviser to DBT and now managing director of New Delhi-based KEE GAD Biogen, a biopharma company. This is a wasted opportunity considering the expected growth in biotech activity.

According to the London-based consultancy firm KPMG, biopharma already constitutes about 70% of the domestic biotech industry, and they predict biotech business will grow to $5 billion by 2010 from $2 billion last year.

At present, Indian firms are only producing copies of established biologic drugs such as recombinant insulin, interferon alpha and erythropoietin and starting to move into monoclonal antibodies and recombinant vaccines. But a DBT five-year plan approved last year gives the highest priority to new biological entity discovery.

The KMPG report says a few companies like Glenmark Pharmaceuticals are already breaking into the novel biologicals space. "In the past most of our programs were aimed at academic collaborations," says S. Natesh, head of DBT's international division. "Our new calls for proposals, hopefully, will bring in industrial collaboration."

The Indian government also expects to expand opportunities for research and training once its $10 million regional biotech center being set up near New Delhi in partnership with UNESCO is ready.

Source: Medindia
GPL/S
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.


Recommended Reading
Biotech Patent System Broken: Research
After conducting case studies in India, Brazil, Canada, Kenya the United States, the European ......

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use